Inflammation plays a pivotal role in peripheral artery disease (PAD). Cellular adhesion proteins mediate the interaction of leukocytes with endothelial cells during inflammation. To determine the association of cellular adhesion molecules with ankle–brachial index (ABI) and ABI category (≤1.0 vs >1.0) in a diverse population, 15 adhesion proteins were measured in the Multi-Ethnic Study of Atherosclerosis (MESA). To assess multivariable associations of each protein with ABI and ABI category, linear and logistic regression was used, respectively. Among 2364 participants, 23 presented with poorly compressible arteries (ABI > 1.4) and were excluded and 261 had ABI ≤ 1.0. Adjusting for traditional risk factors, elevated levels of soluble P-selectin, hepatocyte growth factor, and secretory leukocyte protease inhibitor were associated with lower ABI (P = .0004, .001, and .002, respectively). Per each standard deviation of protein, we found 26%, 20%, and 19% greater odds of lower ABI category (P = .001, .01, and .02, respectively). Further investigation into the adhesion pathway may shed new light on biological mechanisms implicated in PAD.
GoASMozaffarianDRogerVL. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.
2.
FowkesFGMurrayGDButcherI. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208.
3.
CriquiMHMcClellandRLMcDermottMM. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56(18):1506–1512.
4.
McDermottMMLiuKCriquiMH. Ankle-brachial index and subclinical cardiac and carotid disease: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2005;162(1):33–41.
5.
HertzerNRBevenEGYoungJR. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199(2):223–233.
6.
KlopRBEikelboomBCTaksAC. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg. 1991;5(1):41–45.
7.
HealdCLFowkesFGMurrayGDPriceJF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis. 2006;189(1):61–69.
8.
BrevettiGGiuglianoGBrevettiLHiattWR. Inflammation in peripheral artery disease. Circulation. 2010;122(18):1862–1875.
9.
WildmanRPMuntnerPChenJSutton-TyrrellKHeJ. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002. Am J Cardiol. 2005;96(11):1579–1583.
10.
TzoulakiIMurrayGDLeeAJRumleyALoweGDFowkesFG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112(7):976–983.
11.
VidulaHTianLLiuK. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008;148(2):85–93.
12.
BledaSDe HaroJAcinFVarelaCEsparzaLLopez de MaturanaI. Inflammatory burden predicts long-term outcomes in endovascular therapy in peripheral arterial disease. Ann Vasc Surg. 2013;27(4):459–466.
13.
TzoulakiIMurrayGDLeeAJRumleyALoweGDFowkesFG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28(3):354–362.
14.
AllisonMACriquiMHMcClellandRL. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;48(6):1190–1197.
15.
PradhanADRifaiNRidkerPM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002;106(7):820–825.
HwangSJBallantyneCMSharrettAR. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96(12):4219–4225.
18.
RidkerPMHennekensCHBuringJERifaiN. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843.
19.
RidkerPMHennekensCHRoitman-JohnsonBStampferMJAllenJ. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351(9096):88–92.
20.
KhaleghiMAliZMosleyTHJrTurnerSTKulloIJ. Association of soluble cell adhesion molecules with ankle-brachial index in a biethnic cohort of predominantly hypertensive individuals. Clin Chem. 2008;54(11):1788–1795.
21.
BildDEBluemkeDABurkeGL. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871–881.
22.
AboyansVCriquiMHMcClellandRL. Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA). J Vasc Surg. 2007;45(2):319–327.
23.
ChobanianAVBakrisGLBlackHR. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.
24.
LeveyASStevensLASchmidCH. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
25.
BlannAMorrisJMcCollumC. Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin. Atherosclerosis. 1996;126(2):227–231.
26.
TanKTTayebjeeMHLyndCBlannADLipGY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med. 2005;37(1):61–66.
27.
MurabitoJMKeyesMJGuoCY. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study. Atherosclerosis. 2009;203(2):509–514.
28.
BennettPCGillPSSilvermanSBlannADChackathayilJLipGY. Hemostatic cardiovascular risk factors, common carotid-intima medial thickness and peripheral arterial disease in South Asians and African Caribbeans: a substudy to the Ethnic-Echocardiographic Heart of England Screening (E-ECHOES) study. J Thromb Homeost. 2011;9(4):645–652.
29.
JinHWyssJMYangRSchwallR. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des. 2004;10(20):2525–2533.
30.
LiYTakemuraGKosaiK. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation. 2003;107(19):2499–2506.
MakinoHAokiMHashiyaN. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2012;32(10):2503–2509.
33.
LinJWSheuWHLeeWJ. Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease. Angiology. 2007;58(4):420–428.
34.
YoshitomiYKojimaSUmemotoT. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab. 1999;84(7):2425–2428.
35.
RajpathakSNWangTWassertheil-SmollerS. Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women’s Health Initiative. Stroke. 2010;41(5):857–862.
36.
CrossDSMcCartyCAHytopoulosE. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr Med Res Opin. 2012;28(11):1819–1830.
37.
SusenSSautiereKMouquetF. Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization. Eur Heart J. 2005;26(22):2387–2395.
38.
LamblinNSusenSDagornJ. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J. 2005;150(1):137–143.
39.
RychliKRichterBHohensinnerPJ. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart. 2011;97(14):1158–1163.
40.
MadonnaRCevikCNasserMDe CaterinaR. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. Thromb Haemost. 2012;107(4):656–661.
41.
SchneebergerSHautzTWahlSM. The effect of secretory leukocyte protease inhibitor (SLPI) on ischemia/reperfusion injury in cardiac transplantation. Am J Transplant. 2008;8(4):773–782.
42.
WangXLiXXuL. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol Pharmacol. 2003;64(4):833–840.
43.
BarrosSCMartinsJAMarcosJCCavaco-PauloA. Influence of secretory leukocyte protease inhibitor-based peptides on elastase activity and their incorporation in hyaluronic acid hydrogels for chronic wound therapy. Biopolymers. 2012;98(6):576–590.
44.
IlzeckaJStelmasiakZ. Increased serum levels of endogenous protectant secretory leukocyte protease inhibitor in acute ischemic stroke patients. Cerebrovasc Dis. 2002;13(1):38–42.
45.
BobryshevYVLordRSWatanabeTIkezawaT. The cell adhesion molecule E-cadherin is widely expressed in human atherosclerotic lesions. Cardiovasc Res. 1998;40(1):191–205.
46.
MallatZGojovaAMarchiol-FournigaultC. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89(10):930–934.
47.
KugeYTakaiNIshinoSTemmaTShiomiMSajiH. Distribution profiles of membrane Type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull. 2007;30(9):1634–1640.
48.
van der MeerIMde MaatMPBotsML. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2002;22(5):838–842.
49.
De BellisADi MartinoSFiordelisiF. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves’ disease patients followed up for development of ophthalmopathy. J Clin Endocrinol Metab. 1998;83(4):1222–1225.
50.
GiovannoniGLaiMThorpeJ. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology. 1997;48(6):1557–1565.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
